Illumina, Inc. vs Prospect Capital Corporation — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while Prospect Capital Corporation trades at $2.17 (market cap $1.12B). The key difference: Illumina, Inc. is far larger — about 24.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 22.42% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | PSEC | |
|---|---|---|
Market Cap | $27.94B | $1.12B |
Sector | Health | Financials |
52-Week High | $194.33 | $3.47 |
52-Week Low | $91.00 | $2.15 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 22.42% |
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →